INGN
Inogen, Inc.6.81
-0.02-0.29%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details shifts, ramps
Q&A clarified Q4's order shifts shaved ~200bps off revenue, with some already shipped in Q1 and rest sprinkled through H1, while B2B POC demand surges mid-single digits amid rising new-patient POC adoption to 60%. DTC sales narrowed to -15% YoY decline, sequentially better. Aurora CPAP ramps back-end loaded via B2B with strong early therapist and patient feedback; Simeox's $6M global cash-pay haul stemmed from steady uptake plus Eastern Europe tender, fueling trial confidence. More 2026 R&D spend tempers quarterly EBITDA but full-year positivity expected. Order shifts sting Q1, but fade. Management stayed crisp, investors eye launch traction.
Key Stats
Market Cap
184.88MP/E (TTM)
-Basic EPS (TTM)
-1.00Dividend Yield
0%Recent Filings
10-K
FY2025 results
Inogen posted FY2025 revenue of $348.7M, up 3.9% y/y, driven by 18.4% international sales growth to $138.8M (39.8% of total) while U.S. sales dipped 3.1% to $156.5M; sales units jumped 20.3% to 189,400 systems. Q4 momentum shone through with sustained demand from European partners, yet U.S. rentals fell 6.3% y/y to $53.4M amid lower private-payor rates and fewer patients on service. Gross margins slipped to 44.2% from 46.1% on sales mix shifts and chip cost premiums, but operating expenses dropped 6.5% to $184.5M via media cuts and efficiency gains. Cash stood at $103.7M post-$27.2M Yuwell infusion, funding $10.4M rental capex; no debt. Medicare reimbursement volatility threatens quarterly flows.
8-K
Q4 results, buyback authorized
8-K
Inogen prelim revenues up 4%
10-Q
Q3 FY2025 results
Inogen posted Q3 revenue of $92.4M, up 4.0% y/y, driven by 5.6% sales growth to $79.1M while rentals dipped 4.4%; gross margin slipped to 44.7% from 46.5% on sales mix shift. Operating loss narrowed to $7.1M from $7.8M as sales/marketing and G&A expenses fell, though R&D rose 37.6%; diluted EPS improved to -$0.20 from -$0.25, consistent with 27.1M shares and anti-dilution. Cash sits at $106.5M plus $16.7M marketable securities, no debt; YTD operating cash used $10.3M. Raised $27.2M via Yuwell stock deal in Feb 2025. Medicare reimbursement shifts pose reimbursement risk.
8-K
Q3 revenue up 4%, EBITDA positive
Inogen posted Q3 revenue of $92.4 million, up 4.0% year-over-year, its seventh straight mid-single-digit quarter, fueled by 18.8% B2B international sales growth yet offset by DTC declines. Adjusted EBITDA hit $2.3 million; cash swelled to $124.5 million. Growth persists. Reiterates full-year revenue at $354-357 million, lifts adjusted EBITDA to ~$2 million.
AXGN
AxoGen, Inc.
29.35-0.43
IINN
Inspira Technologies Oxy B.H.N.
1.02-0.03
INMD
InMode Ltd.
14.48+0.15
INSP
Inspire Medical Systems, Inc.
115.51-3.75
IRME
IR-Med Inc.
0.02-0.01
NVNO
enVVeno Medical Corporation
0.32+0.01
PODD
Insulet Corporation
288.73-2.78
RMD
ResMed Inc.
247.34-5.73
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00
TGEN
Tecogen Inc.
5.34-0.50